Ampersand Capital Partners a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, today announced the acquisition of CurTec Group B.V. ("CurTec"), a Netherlands-based manufacturer of high-performance plastic packaging solutions for pharmaceutical and specialty chemical applications from Bencis Capital Partners ("Bencis") in partnership with management.
"We are thrilled to welcome Ampersand as our new partner as we focus on scaling U.S. operations, advancing product innovation, expanding our footprint and growing into adjacent markets," said Bart van Berkel, CEO of CurTec. "Their deep expertise in the life sciences supply chain and their US network will help accelerate our global presence while reinforcing our commitment to quality, innovation, and sustainability."
"CurTec is a premium brand trusted by leading pharmaceutical companies - including those within Ampersand's portfolio - for its exceptional product quality and regulatory standards," said Hidde Van Kerckhoven, Principal at Ampersand. "We look forward to working closely with Bart and his team to expand capacity, strengthen commercial capabilities, and support long-term growth."
"We look back on a very successful partnership with CurTec and the team, evolving into a global leader in regulated packaging through innovation, operational and ESG excellence, and a clear focus on pharma," said Zoran van Gessel, Managing Partner at Bencis. "It's been a pleasure supporting CurTec over all those years together with Fred Lammers, the former CurTec CEO, and we wish the team and Ampersand continued success in this next chapter."
Comments powered by CComment